How pharma payments influence rheumatology drug use; fight over opioid prescriptions heads to Supreme Court

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: FTC will vote on whether to examine how PBM practices may hurt pharmacies and drug prices By Ed Silverman Alex Brandon/AP The FTC plans to vote later this month on whether to examine pharmacy benefits managers and their controversial practices. Read More STAT+: Drug company payments for consulting, food, and drinks influence rheumatologists' prescribing By Ed Silverman APStock The study found for every $100 in food and beverage payments, the probability of prescribing rose from 1.5% to 14%, depending upon the drug. Read More Fight over opioid prescribing — and when it turns criminal — heads to Supreme Court By Andrew Joseph Alex Hogan/STAT A ruling could enable aggressive prosecutions of prescribers' opioid prescribing, and lead to prescribers dropping pain patients from care. Read More Sponsor content by RARE ACCESS ACTION PROJECT Congress can score a win, without making patients lose Right now, politicians need a win, but rare disease patients could lose. In Congress' rush to pass something, they're considering putting huge cost increases on the development of treatments for rare diseases — increasing costs 400-800%. Tell Congress there is a better way that protects patients. Learn more at RareAccessActionProject.org. Authorization of new Covid-19 monoclonal expands arsenal of options against Omicron and its sister variant By Andrew Joseph The FDA authorized another Covid-19 monoclonal antibody treatment, expanding the supply of treatments that work against the Omicron variant. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More STAT+: An FDA ruling on Cassava's Alzheimer's drug leaves bulls and bears waiting for more By Adam Feuerstein While the decision was a win for Cassava, a top official did not rule out further action against the company. Read More Friday, February 11, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser